QIAGEN (QGEN) Stock: Buy, Sell, or Hold?
QGEN - QIAGEN N.V.
$50.36
0.35 (0.71%)
▲
5d:
+9.06%
30d:
+15.2%
90d:
+21.72%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 03, 2026
11d
Get Alerted When QGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: QGEN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: QGEN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$55.35
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$34.37
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: QGEN is currently trading at $50.35, which is considered extended relative to its 30-day fair value range of $43.11 to $46.61. From a valuation perspective, the stock is trading at a premium (Forward PE: 19.1) compared to its historical average (16.1). At these levels, the market is pricing in 5.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, QGEN is in a strong uptrend. The price is approaching resistance at $50.82. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: QGEN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QGEN is in a strong uptrend. The price is approaching resistance at $50.82. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: QGEN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$43.11 -
$46.61
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
18.1%
All Signals
- BEARISH: Price extended above range (+8.0% above its trading range)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($48.20)
- NEUTRAL: Trading at premium valuation - market expects 5.9% growth which is achievable
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$43.11 -
$46.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$43.65
Resistance Level
$50.82
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.14
Wall Street Target
$48.20
(-3.6%)
Revenue Growth (YoY)
0.3%
Earnings Growth (YoY)
7.9%
Profit Margin
19.5%
Valuation Premium vs History
+5.9% premium
PE vs Historical
19.1 vs 16.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.9%
(market-implied from PE analysis)
1-Year Target
$52.95
(+6%)
2-Year Target
$56.07
(+12%)
3-Year Target
$59.38
(+19%)
3-Yr Target (if PE normalizes)
(PE: 19→16)
PE COMPRESSION
$49.96
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 7.3%)
$64.14
(+28%)
Base:
(SPY PE: 19.1, Growth: 7.3%)
$61.81
(+24%)
Bear:
(PE: 16.1, Growth: 7.3%)
$52.00
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 24.82 | Current EPS (TTM): $1.97
Bull Case
$71.34
(+43%)
Analyst growth 32.6%, PE expands to 27.3
Base Case
$64.85
(+30%)
Market implied 32.6%, PE stable at 24.8
Bear Case
$33.25
(-34%)
Severe decline -20.0%, PE contracts to 21.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 10:14 AM ET
Data refreshes hourly during market hours. Next update: 11:14 AM
Data refreshes hourly during market hours. Next update: 11:14 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GH
Guardant Health Inc |
STRONG BUY
26 analysts |
$202 | 61 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
28 analysts |
$691 | 42 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$244 | 40 SELL |
|
NTRA
Natera Inc |
STRONG BUY
23 analysts |
$404 | 44 HOLD |
